Clinical Trial

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Study acronym: JACKPOT38
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, phase 2 study to evaluate the safety and efficacy of golidocitinib with PD-1 inhibitors as maintenance treatment in patients with previously untreated extensive-stage small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-31.
Status change: Not Yet Recruiting → Recruiting 2026-02-25
Trial Details
NCT Number NCT07110103
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Conditions SCLC, SCLC, Extensive Stage
Enrollment 20 participants
Start Date 2025-10-31
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27